Bristol Myers Squibb Company (NYSE:BMY) has announced five innovative biotech startups as winners of the company’s 2021 Golden Ticket Contests. The winners are: RADD Pharmaceuticals and Rubik Therapeutics (LabCentral, Cambridge, MA), Waypoint Bio (BioLabs@NYULangone, New York, NY) and Altay Therapeutics and VastBiome (MBC BioLabs, San Francisco Bay Area, CA).
“These Golden Tickets are an important way for us to foster growth of life science startup companies and bolster the communities in which we work and live,” said Kristen Hege, M.D., Senior Vice President, Early Clinical Development, Hematology/Oncology and Cell Therapy and San Francisco site head. “A core part of our philosophy is to encourage interdisciplinary collaborations and novel approaches. Our goal is that BMS’ general support of the three incubators and our specific contribution to companies within them will help spur the next wave of scientific breakthroughs that lead to development of new medicines that improve the lives of people with serious diseases.”
Bristol Myers Squibb has annually held the Golden Ticket contest since it began in Cambridge in 2016 for promising biotech start-ups pursuing research in novel target identification, drug delivery, discovery technology platforms or translational R&D in a variety of therapeutic research fields. The Golden Ticket contest provides recipient companies with one year of fully equipped, permitted and supported lab space for biomedical research, plus programming and networking opportunities through these incubators to help advance their science and build their companies.
